LivaNova’s Perceval Sutureless Aortic Heart Valve Receives National Reimbursement in Japan to Treat Patients with Aortic Valve Disease

LivaNova PLC, a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval®sutureless aortic heart valve to treat aortic valve disease. By adding Perceval into Japan’s health insurance system, physicians and patients have greater access to this versatile biological heart valve.